Jeppe Øvlesen is a seasoned executive and biotech entrepreneur with a strong commercial background and a solid deal-making track record. Mr. Øvlesen has more than 20 years´ experience at the executive level and has been involved in a string of successful start-up companies, including Action Pharma, Biostrip, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, Mindway and TXP Pharma. In these companies, Mr. Øvlesen has served as co-founder, CEO and/or chairman/board member and has overseen the transition from startup, build up to successful exit. Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on the Swedish stock exchange Spotlight.
Holdings: 1 396 583
Chief Medical Officer
Dr. Duvauchelle is one of Europe’s most experienced experts in clinical pharmacology and has more than 25 years of experience in early clinical development. Dr. Duvauchelle has for many years been the head of Paris’ largest phase 1 clinic, Aster-Cephac, and held the position of Corporate VP in SGS, with responsibility for the company’s clinical phase 1 clinics in France and Belgium.
Dr. Duvauchelle does not hold shares in SynAct Pharma AB.
Thomas Jonassen is associate professor at Cardiovascular Pharmacology, University of Copenhagen and visiting professor at William Harvey Research Institute, Barts and London School of Medicine. Jonassen has published more than 50 scientific publications and is inventor of 6 granted patents in USA and Europe.
Jonassen is co-founder and current CSO at SynAct Pharma AB, co-founder of ResoTher Pharma Aps and co-founder and former CSO at Action Pharma A/S and co-founder of TXP Pharma Gmbh. Action Pharma sold its lead drug development candidate to AbbVie for 110 MUSD and TXP Pharma sold various rights to Questcor Pharmaceuticals for 100 MUSD in milestone payments.
Jonassen is co-inventor of SynActs drug candidate AP1189.
Jonassen holds shares in SynAct Pharma AB.
Holdings: 2 236 971
Henrik Stage, MSc, has more than 25 years of experience from executive positions in biotech and finance.
Henrik has previously served as CFO and CEO of Santaris Pharma A/S, Denmark. Established in 2000, Santaris Pharma was sold to Hoffmann-La Roche in 2014 for 450m USD in up-fronts and earn-outs. Leading up to the sale to Roche Henrik led the preparation of Santaris IPO at NASDAQ in USA.
As part of the executive management team for more than a decade, Henrik transformed Santaris from a “technology platform company” to a “clinical stage company” with a diverse pipeline of 6 drugs. As part of the management Stage raised +150m USD in dilutive funds from venture capital investors and +150m USD in non-dilutive funds from pharma partners in 10 out-licensing deals with companies like såsom Pfizer, BMS, Roche, GSK och Shire.
Prior to joining the executive management team of Santaris Pharma Henrik held senior executive positions at Carlsberg, FL Smidth, Hempel and Hardi. He has lived and worked in the USA, Canada and Vietnam.
Henrik has been part of the listing of RhoVac and SynAct at SpotLight and is involved in ADCendo ApS and ResoTher ApS.
Henrik earned his MSc. from Copenhagen Business School.
Stage holds 100 procent of the shares in Next Stage Ventures ApS, which hold shares in SynAct Pharma AB.
Holdings: 511 430
Holdings in SynAct Pharma AB as of December 31, 2019.